Yang LM, Wang HJ, Li SL, Gan GH, Deng WW, Chang YS, Zhang LF. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors. World J Gastroenterol 2024; 30(11): 1533-1544 [PMID: 38617449 DOI: 10.3748/wjg.v30.i11.1533]
Corresponding Author of This Article
Li-Min Yang, MD, Associate Chief Physician, Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou 450052, Henan Province, China. ylmsunny6153@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li-Min Yang, Hong-Juan Wang, Guan-Hua Gan, Wen-Wen Deng, Lian-Feng Zhang, Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Shan-Lin Li, Department of Gastroenterology, Zhoukou Central Hospital of Henan Province, Zhoukou 466000, Henan Province, China
Yong-Sheng Chang, Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, Henan Province, China
Co-corresponding authors: Li-Min Yang and Lian-Feng Zhang.
Author contributions: Yang LM and Zhang LF contributed equally to this work and are co-corresponding authors, including those involved in the design of the study, the acquisition and analysis of the data from the experiments, and the writing of the manuscript. Yang LM, Zhang LF and Wang HJ designed the experiment and conducted the clinical data collection; Li SL and Gan GH performed the postoperative follow-up and recorded the data; Deng WW and Chang YS conducted a number of collations and statistical analyses; all the authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University, and the need to provide informed consent was waived.
Informed consent statement: After review by the Ethics Committee, a waiver of informed consent was granted for this subject.
Conflict-of-interest statement: The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data sharing statement: All the data generated or analyzed during this study are included in this published article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Min Yang, MD, Associate Chief Physician, Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou 450052, Henan Province, China. ylmsunny6153@126.com
Received: January 5, 2024 Peer-review started: January 5, 2024 First decision: January 23, 2024 Revised: February 18, 2024 Accepted: March 8, 2024 Article in press: March 8, 2024 Published online: March 21, 2024 Processing time: 76 Days and 3 Hours
Core Tip
Core Tip: The combination of radiofrequency ablation (RFA) and sorafenib shows promise in treating liver cancer with portal hypertension. This approach demonstrated improved short- and long-term efficacy, with significant reduction in portal vein pressure and enhancement of liver function. Patients treated with this combination had higher survival rates compared to those receiving RFA alone. Moreover, the study identified key prognostic factors, such as Child-Pugh grade, tumor size, history of hepatitis, and the use of sorafenib, providing valuable insights for managing liver cancer complicated by portal hypertension. These findings suggest that the RFA and sorafenib combination could be a beneficial therapeutic strategy, but further research with larger sample sizes is warranted to validate these outcomes.